Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

NCT01207492 is registered in ClinicalTrials.gov with Andrew J. Wagner, MD, PhD as lead sponsor.

NCT NCT01207492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01207492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Lead sponsor
Andrew J. Wagner, MD, PhD
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2010
Completion date
August 31, 2015
Enrollment
17 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse-type giant cell tumor, pigmented villonodular synovitis, tenosynovial giant cell tumor